Why the study?
Does the BNT162b2 mRNA SARS-CoV-2 vaccine increase the risk of myocarditis compared to unvaccinated controls?
Does the BNT162b2 mRNA SARS-CoV-2 vaccine increase the risk of myocarditis compared to unvaccinated controls?
The BNT162b2 mRNA vaccine is associated with a low incidence of generally mild myocarditis.
Two papers reported retrospective data on cases of presumed myocarditis that were detected after receipt of the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) in Israel. Witberg et al. 1 searched the database of Clalit Health Services, the largest Healthcare Organization (HCO) in Israel, for diagnoses of myocarditis in patients who had received at least one dose of the BNT162b2 mRNA vaccine, from December 2020 to May 2021. Mevorach et al. 2 reviewed data from medical records obtained from the Israeli Ministry of Health regarding hospitalized patients with suspected myocarditis among vaccinated persons, when compared with unvaccinated controls, from December 2020 to May 2021. Witberg et al. 1 identified 54 cases that fulfilled the definition of myocarditis used by the Centers for Disease Control and Prevention
No takes yet. Share an insight, caveat, or question.
Liuzzo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: